NCT06910618

Brief Summary

Vertebral fracture is a common clinically significant skeletal related event in cancer patients. Stratification of patients diagnosed with one or more vertebral metastases according to the risk of pathological fracture is an unresolved problem despite the fact that fractures strongly influence the quality of life (QoL) and also the overall survival. The multidimensional nature and the strong patient specificity of the risk for fracture have not been considered in previously published risk estimation models and these methods were developed and validated only on retrospective data focusing on prevalence of life-time fracture which is not really relevant at the time of the diagnosis of a vertebral metastasis. To overcome these shortcomings, the METASTRA models (METASTRA-AI and METASTRA-VPH) and the decision support system (METASTRA-DSS) are developed considering the highest possible level of patient specificity to stratify the individuals according to their risk for fracture in a clinically considerable period (within next 6 months). The prospective data collection and analysis will provide reliability and validity results on the performance of METASTRA tools as well as structured information on user's experience helping the future integration of the developed patient-specific stratification tool into the everyday clinical practice. The study is a prospective clinical data collection from minimum 200 patients to determine the validity (i.e. Precision) in fracture risk stratification of the METASTRA-AI and METASTRA-VPH computational models and to determine the reliability of METASTRA-AI and METASTRA-VPH as well as human decision making process in patient stratification.

Trial Health

67
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
15mo left

Started Apr 2025

Typical duration for all trials

Geographic Reach
4 countries

4 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress47%
Apr 2025Aug 2027

First Submitted

Initial submission to the registry

March 28, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

April 1, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 4, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2027

Expected
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

April 4, 2025

Status Verified

March 1, 2025

Enrollment Period

2 years

First QC Date

March 28, 2025

Last Update Submit

March 28, 2025

Conditions

Keywords

vertebral metastasiscancerfracturerisk stratification

Outcome Measures

Primary Outcomes (1)

  • new vertebral fracture

    in 6 months

Study Arms (1)

Patients with vertebral metastasis in ThL region

Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)

You may qualify if:

  • Patient 18 years or older
  • Patient diagnosed with a metastatic tumor in the thoracic and/or lumbar spine (one or more vertebral metastases in the spinal region between T1 and L5 vertebrae)
  • Min. 1 vertebra is potentially unstable based on SINS score (SINS is 7-12) and it has not been surgically stabilized previously (level of interest - LOI)
  • Adjacent vertebrae are not surgically stabilized at the time of the enrollment
  • Patient willing to complete 6-month follow-up
  • Patient is willing and able to provide written informed consent after the nature of the study has been explained:
  • Ability to understand the content of the patient information/ ICF
  • Willingness and ability to participate in the study according to the protocol
  • Signed and dated EC approved written informed consent

You may not qualify if:

  • Poor general status at baseline (Karnofsky scale less than 40%)
  • Expected life expectancy is less than 3 months at baseline
  • Spinal infection
  • Ongoing litigation
  • Participation in investigational clinical study at the same time or within 3 months
  • Vertebral lesion/metastasis from a hematologic condition (e.g. multiple myeloma)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Department of Neurosurgery Charité Berlin

Berlin, Germany

Location

Buda Health Center

Budapest, 1126, Hungary

Location

IRCCS Istituto Ortopedico Rizzoli

Bologna, Italy

Location

University Medical Center Utrecht

Utrecht, Netherlands

Location

MeSH Terms

Conditions

Spinal FracturesNeoplasmsFractures, Bone

Condition Hierarchy (Ancestors)

Spinal InjuriesBack InjuriesWounds and Injuries

Central Study Contacts

Aron Lazary, MD PhD

CONTACT

Julia Szita, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2025

First Posted

April 4, 2025

Study Start

April 1, 2025

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

August 1, 2027

Last Updated

April 4, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations